Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 13, 2016 7:18 PM ET

Biotechnology

Company Overview of Allakos Inc.

Company Overview

Allakos Inc., a biotechnology company, develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory responses. Allakos Inc. was founded in 2012 and is based in San Mateo, California.

132 Avila Road

San Mateo, CA 94402

United States

Founded in 2012

Phone:

650-703-8123

Key Executives for Allakos Inc.

Founder, Chief Executive Officer, President and Director
Co-Founder and Vice President of Research
Chief Medical Officer
Age: 54
Compensation as of Fiscal Year 2015.

Allakos Inc. Key Developments

Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001

Allakos Inc. announced that it has successfully completed dosing in the Phase 1 clinical trial of AK001 in healthy volunteers and subjects with atopic disease. AK001 is a therapeutic antibody intended for the treatment of severe allergic diseases and diseases characterized by excess activity of mast cells and eosinophils. The randomized, double-blind, placebo-controlled, single-ascending-dose study enrolled 34 subjects to evaluate the safety, tolerability and pharmacokinetics of AK001 in a range of potentially active doses and to obtain early signals of pharmacodynamic activity.

Allakos Inc. Appoints Alejandro Dorenbaum as Chief Medical Officer

Allakos Inc. announced the appointment of Alejandro Dorenbaum as Chief Medical Officer. At BioMarin Pharmaceutical Inc., he was responsible for the clinical development of Kuvan(R), and at Genentech, he was responsible for the respiratory programs in asthma and cystic fibrosis. Dr. Dorenbaum also served as Chief Medical Officer at Lumena Pharmaceutical until its acquisition by Shire.

Similar Private Companies By Industry

Company Name Region
Signalway Antibody Co.,Ltd United States
Vet Therapeutics, Inc. United States
Pearl Lifescience Partners, LLC United States
Universal Preservation Technologies, Inc. United States
Parallel Solutions, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Allakos Inc., please visit www.allakos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.